• 2025
• 2024
• 2023
• 2022
• 2021
• 2020
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002
• 2001
• 2000
• 1999
• 1998
• 1997
• 1996
• 1995
• 1993

2025

• Patrick Opitz1, Isabel Waltering1, and Georg Hempel1, * 1. Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Muenster, and Muenster, Germany. 2025. “Development and Validation of a Quantification Method for Direct Oral Anticoagulants from Capillary Blood using volumetric absorptive microsampling and online SPE-LC-MS.” Journal of Chromatography B, № 1251 124423. doi: https://doi.org/10.1016/j.jchromb.2024.124423.

2024

• Zimbelmann, F, Flaute, S, Deipenbrock, M, Ahlke, E, Hempel, G, and Baumann-Köhler, M. 2024. “Anwendung stark wirksamer retardierter Opioide in der Pädiatrie : Fallstricke und Lösungen für Morphin und Hydromorphon.” Schmerz, № 204 doi: 10.1007/s00482-023-00775-w.
• Bauch, T, and Hempel, G. 2024. “Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.” British Journal of Haematology, № 204 (6): 2324–2331. doi: 10.1111/bjh.19410.
• Opitz, P, Fobker, M, Fabian, J, and Hempel, G. 2024. “Development and validation of a bioanalytical method for the quantification of methotrexate from serum and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.” Journal of Chromatographic Science, № 1715 464610. doi: 10.1016/j.chroma.2023.464610.
• Ramadan, O.[1], Opitz, P.[2 3], and Hempel, G.[4]. 2024. “Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using Dried Blood Spots.” Therapeutic Drug Monitoring, № 00: 1–7. doi: 10.1097/FTD.0000000000001202.

2023

• Schatz, LM, Brinkmann, A, Röhr, A, Frey, O, Greppmair, S, Weinelt, F, Zoller, M, Scharf, C, Hempel, G, and Liebchen, U. 2023. “Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.” Antimicrobial Agents and Chemotherapy, № 1 doi: 10.1128/aac.00104-23.
• Rosser, SPA, McLachlan, AJ, Hempel, G, Chung, J, Shaw, PJ, Keogh, SJ, and Nath, CE. 2023. “Validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide and N-monomethylacetamide in pediatric plasma.” Journal of Separation Science, № 46 (10) doi: 10.1002/jssc.202201003.
• Ramadan O, Schatz LM, van den Heuvel I, Masjosthusmann K, Groll AH, Hempel G. 2023. “Developing a Method for Quantifying Meropenem in Children-Volumetric Adsorptive Microsampling Versus Plasma Sampling.” Therapeutic Drug Monitoring, № 45 (5): 623–630.
• Gastine, SE; Rauwolf, KK; Pieper, S; Hempel, G; Lehrnbecher, T; Tragiannidis, A; Groll, AH. 2023. “Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.” Mycoses, № 66 (11): 969–976.
• Maierhöfer, S, Waltering, I, Würthwein, G, Jacobs, M, and Hempel, G. 2023. “Ein klinisches Entscheidungsunterstützungssystem für Medikationsanalysen in öffentlichen Apotheken: patientenberichtete Endpunkte der OPtiMed-Studie.” contributed to the Annual Meeting of the German Society of Clinical Pharmacy – DGKPha, Münster
• Opitz, P, Zimmermann, S, Stapf, M, Klima, F, Müller, L, Fuxius, S, Illerhaus, G, Scherf-Clavel, O, Kloft, C, and Hempel, G. 2023. “Erweiterung einer bioanalytischen Methode für das therapeutische Drug Monitoring von Axitinib in Plasma und Kapillarblut zu einer generischen Methode für orale Onkologika.” contributed to the Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie DGKPha, Münster

2022

• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Von Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, and Lanvers-Kaminsky, C. 2022. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica, № 107 (1) doi: 10.3324/haematol.2020.258525.
• Bognàr, T, Bartelink, IH, Egberts, T, Rademaker, C, Versluys, B, Slatter, MA, Kletzel, M, Nath, CE, Cuvelier, GDE, Savic, RM, Dvorak, C, Long-Boyle, JR, Cowan, MJ, Bittencourt, H, Bredius, M, Güngör, T, Shaw, PJ, Ansari, M, Hassan, M, Krajinovic, M, Hempel, G, Marktel, S, Chiesa, R, Théoret, Y, Lund, T, Orchard, PJ, Wynn, RRF, Boelens, J, and Lalmohamed, A. 2022. “Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.” Cellular Therapy and Transplantation, № 22 doi: 10.1016/j.jtct.2022.01.013.
• Khalil, A; Würthwein, G; Golitsch, J; Hempel, G; Fobker, M; Gerss, J; Möricke, A; Zimmermann, M; Smisek, P; Zucchetti, M; Nath, C; Attarbaschi, A; Von Stackelberg, A; Gökbuget, N; Rizzari, C; Conter, V; Schrappe, M; Boos, J; Lanvers-Kaminsky, C. 2022. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica, № 107 (1): 49–57. doi: 10.3324/haematol.2020.258525.
• Opitz, Patrick, Zimmermann, Sebastian, Mc Laughlin, M.Anna, Müller, Lothar, Fuxius, Stefan, Illerhaus, Gerald, Scherf-Clavel, Oliver, Kloft, Charlotte, and Hempel, Georg. 2022. “Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.” Journal of Pharmaceutical and Biomedical Analysis, № 221 115033. doi: 10.1016/j.jpba.2022.115033.
• Lea Marie Schatz, Georg Hempel, and Ferdinand Anton Weinelt, Uwe Liebchen. 2022. “Systematic evaluation of meropenem pharmacokinetic models for Bayesian forecasting in critically ill patients undergoing continuous renal replacement therapy.” contributed to the Quantitative Systems Pharmacology Conference 2022, Leiden
• Schatz, Lea Marie, Wicha, Sebastian G., Hempel, Georg, de Hoog, Matthijs, Allegaert, Karel, Knibbe, CatherijneA.J, and Völler, Swantje. 2022. “Model-informed precision dosing for vancomycin in children between 28 days and 18 years: Does the use of a multi-model approach improve the predictive performance?” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana
• Hirn-Derksen, B., Ryu, C., Hyunki, C., Kim, J.Y., and Hempel, G. 2022. “Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos.” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana
• Shahhossini, Morwarid, Lehmann, Florian, Schmidt, Christina, Arnemann, Philip-Helge, Kaiser, Luca Elisa, Ertmer, Christian, Hempel, Georg, and Hessler, Michael. 2022. “Plasmakonzentration von Vancomycin nach Hämadsorption mit Cytosorb®.” contributed to the Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI), Hamburg
• Morwarid, Shahhossini., Hessler, Michael, and Hempel, Georg. 2022. “Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock.” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana
• Mohamed, Fakry F., Anhlan, Darisuren, Schöfbänker, Michael, Schreiber, André, Classen, Nica, Hensel, Andreas, Hempel, Georg, Scholz, Wolfgang, Kühn, Joachim, and Hrincius, Eike R. Stephan Ludwig. 2022. “Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.” Pharmaceuticals, № 15 (5) doi: 10.3390/ph15050530.
• Maierhöfer, S; Waltering, I; Jacobs, M; Würthwein, G; Appelrath, M; Koling, S; Hempel, G. 2022. “Decision support software-guided medication reviews in elderly patients with polypharmacy: a prospective analysis of routine data from community pharmacies (OPtiMed study protocol).” Journal of Pharmaceutical Policy and Practice, № 15 (1) doi: 10.1186/s40545-022-00495-z.
• Maierhöfer, S, Waltering, I, Jacobs, M, Appelrath, M, and Hempel, G. 2022. “Developing a questionnaire comprising clinically useful patient-reported outcome measures in software-assisted medication reviews.” contribution to the Jahrestagung der deutschen Gesellschaft für klinische Pharmazie, Heidelberg

2021

• Spiegler, V, Greiffer, L, Jacobtorweihen, J, Asase, A, Lanvers-Kaminsky, C, Hempel, G, Agyare, C, and Hensel, A. 2021. “In vitro screening of plant extracts traditionally used as cancer remedies in Ghana - 15-Hydroxyangustilobine A as the active principle in Alstonia boonei leaves.” Journal of Ethnopharmacology, № 2021 doi: 10.1016/j.jep.2020.113359.
• Rimmler, Ch, Lanckohr, Ch, Mittrup, M, Welp, H, Würthwein, G, Horn, D, Fobker, M, Ellger, B, and Hempel, G. 2021. “Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass.” British Journal of Clinical Pharmacology, № 87 (3): 1486–1498.
• Mc, Laughlin AM, Schmulenson, E, Teplytska, O, Zimmermann, S, Opitz, P, Groenland, SL, Huitema, ADR, Steeghs, N, Müller, L, Fuxius, S, Illerhaus, G, Joerger, M, Mayer, F, Fuhr, U, Holdenrieder, S, Hempel, G, Scherf-Clavel, O, Jaehde, U, and Kloft, C. 2021. “Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. For The On-Target Study Consortium.” Cancers, № 13 (24) doi: 10.3390/cancers1324628.
• Blume, H, Mehta, M, Beuerle, G, Dorantes, A, Hempel, G, Jiang, W, Kovar, A, Lee, J, Potthast, H, Schug, B, Seidlitz, A, Tampal, N, Tsang, Y, Walstab, J, and Welink, J. 2021. “The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.” European Journal of Pharmaceutical Sciences, № 2021 doi: 10.1016/j.ejps.2021.105987.
• Barnett, S, Hellmann, F, Parke, E, Makin, G, Tweddle, DA, Osborne, C, Hempel, G, and Veal, GJ. 2021. “Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.” European Journal of Cancer (1965), № 2021 doi: 10.1016/j.ejca.2021.09.014.
• Jalusic, KO, Hempel, G, Arnemann, PH, Spiekermann, C, Kampmeier, TG, Ertmer, C, Gastine, S, and Hessler, M. 2021. “Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis.” British Journal of Clinical Pharmacology, № 87 (6)
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, and Abad-Santos, F. 2021. “Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.” Clinical Pharmacokinetics, № 60 (2)
• Gastine, S, Hope, W, Hempel, G, Petraitiene, R, Petraitis, V, Mickiene, D, Bacher, J, Walsh, TJ, and Groll, AH. 2021. “Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.” Antimicrobial Agents and Chemotherapy, № 65 (2) doi: 10.1128/AAC.01574-20.
• Kneller, LA, Zubiaur, P, Koller, D, Abad-Santos, F, and Hempel, G. 2021. “Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.” Clinical Pharmacokinetics, № 2021 (Jun 14) doi: 10.1007/s40262-021-01041-x.
• Waltering, Isabell, Schwalbe, Olaf, and Hempel, Georg. 2021. “Identification of factors for a successful implementation of medication reviews in community pharmacies: Using Positive Deviance in pharmaceutical care.” International Journal of Clinical Pharmacy, № 44 (1) doi: 10.1007/s11096-021-01315-1.
• Würthwein, G, Lanvers-Kaminsky, C, Siebel, C, Gerß, J, Möricke, A, Zimmermann, M, Stary, J, Smisek, P, Schrappe, M, Rizzari, C, Zucchetti, M, Hempel, G, Wicha, SG, and Boos, J. 2021. “Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.” European Journal of Drug Metabolism and Pharmacokinetics, № 46 (2): 289–300. doi: 10.1007/s13318-021-00670-8.
• Shahhossini, Morwarid, Hessler, Michael, and Hempel, Georg. 2021. “Untersuchung der Adsorption von Ciprofloxacin in vivo nach Hämoadsorption mit CytoSorb®.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital
• Schatz, L.M., Ramadan, O., Groll, A., Masjosthusmann, K., van den Heuvel, A., and Hempel, G. 2021. “Therapeutisches Drug Monitoring und Dosisoptimierung von Meropenem, basierend auf kleinen Probenvolumina bei kritisch kranken Kindern.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), online
• Maierhöfer, S, Waltering, I, Gillessen, A, Würthwein, G, and Hempel, G. 2021. “Effekte Software-gestützter Medikationsanalysen auf die Angemessenheit der Medikation und auf patientenberichtete Endpunkte bei geriatrischen Patienten mit Polypharmazie: eine prospektive Analyse von Routinedaten aus öffentlichen Apotheken (OptiMed- Studienprotokoll).” contributed to the Annual Meeting of the German Society of Clinical Pharmacy - DGKPha, München
• Maierhöfer, S, Waltering, I, Riebel, S, and Hempel, G. 2021. “Effectiveness of clinical decision support systems for managing drug therapy: a systematic review within the scope of a clinical evaluation of a medical device.” contributed to the 12th PCNE working conference, Basel doi: 10.1007/s11096-21-01269-4.
• McLaughlin1, A.M., Schmulenson2, E, Teplytska2, O, Zimmermann3, S, Opitz, P, Groenland4, S.L., Huitema45, A.D.R., Steeghs4, N., Müller6, L., Fuxius7, S., Illerhaus8, G., Joerger9, M., Mayer10, F., Fuhr11, U., Holdenrieder12, S., Hempel, G., Scherf-Clavel3, O., Jaehde2, U., and Kloft1, C. 2021. “Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.” Cancers, № 13 (24): 1–15. doi: 10.3390/cancers13246281.
• Opitz, Patrick, Stern, Mike, and Hempel, Georg. 2021. “Entwicklung und Validierung einer quantitativen Methode zur Bestimmung von direkten oralen Antikoagulantien aus Kapillarblut unter Verwendung von VAMSTM und online SPE-LC-MS.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital

2020

• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, and Hempel, G. 2020. “Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.” Bioanalysis, № 2020 Aug;12(16) doi: 10.4155/bio-2020-0136.
• Hempel, G. 2020. “Methods of Therapeutic Drug Monitoring including Pharmacogenetics 2nd Edition.” in Handbook of Analytical Separations Series Volume 7:, edited by Elsevier B.V. Amsterdam.
• Hensel, A, Bauer, R, Heinrich, M, Spiegler, V, Kayser, O, Hempel, G, and Kraft, K. 2020. “Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.” Planta Medica, № 2020
• Hempel, G. 2020. “How physiologically-based pharmacokinetic models should be improved for drug development.” Future Medicinal Chemistry, № 12 (12) doi: 10.4155/fmc-2020-0074.
• Siebel, C, Würthwein, G, Lanvers-Kaminsky, C, André, N, Berthold, F, Castelli, I, Chastagner, P, Doz, F, English, M, Escherich, G, Frühwald, MC, Graf, N, Groll, AH, Ruggiero, A, Hempel, G, and Boos, J. 2020. “Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.” BMC pharmacology & toxicology, № 21 (1) doi: 10.1186/s40360-020-00417-2.
• Dallmann, A, Himstedt, A, Solodenko, J, Ince, I, Hempel, G, and Eissing.T. 2020. “Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery.” Journal of Pharmacokinetics and Pharmacodynamics, № 47 (4)
• Hellmann, F, Völler, S, Krischke, M, Jamieson, D, André, N, Bisogno, G, Boddy, A, and Hempel, G. 2020. “Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.” European Journal of Drug Metabolism and Pharmacokinetics, № 45 (3)
• Berning, P, Hennemann, C, Tulotta, C, Schaefer, C, Lechtape, B, Hotfilder, M, El, Gourari Y, Jürgens, H, Snaar-Jagalska, E, Hempel, G, Dirksen, U, and Potratz, J. 2020. “The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.” Cancers, № 12 (4)
• Kneller, LA, and Hempel, G. 2020. “Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients.” in Vol. 53 of Pharmacopsychiatry 2020 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710122.
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2020. “Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.” Clinical Pharmacokinetics, № 59 (1) doi: 10.1007/s40262-019-00793-x.
• Kneller, LA, and Hempel, G. 2020. “Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.” Pharmaceutical Research, № 37 (6) doi: 10.1007/s11095-020-02843-7.
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, and Abad-Santos, F. 2020. “Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.” Clinical Pharmacokinetics, № 60 (2) doi: 10.1007/s40262-020-00941-8.
• Waltering, I, Scheppe, S, Kurth, V, Hempel, G, and Jaehde, U. 2020. “Qualitätsindikatoren zur Bewertung von Medikationsanalysen in öffentlichen Apotheken. (Quality indicators for medication reviews in community pharmacies).” Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, № 153-154 doi: 10.1016/j.zefq.2020.03.007.
• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, and Hempel, G. 2020. “Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.” Bioanalysis, № 12 (16) doi: 10.4155/bio-2020-0136.
• Stern, M, and Hempel, G. 2020. “Clinical validation study to derive conversion factors from capillary blood to plasma concentration for mirtazapine, quetiapine and norquetiapine.” contribution to the IATDMCT 2020, Canada
• Lücht, UR, Geiben, AK, Brune, S, Scholz, WU, and Hempel, G. 2020. “Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals.” in Pharmacopsychiatry , Vol. 3 of 53 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710124.
• Siebel, Ch, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, and Boos, J. 2020. “Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring.” Scientific Reports, № 1 Vol (10): 18562. doi: 10.1038/s41598-020-75662.
• Dellinger, JK, Pitzer, S, Schaffler-Schaden, D, Schreier, MM, Fährmann, LS, Hempel, G, Likar, R, Osterbrink, J, and Flamm, M. 2020. “Improving medication appropriateness in nursing homes via structured interprofessional medication-review supported by health information technology: a non-randomized controlled study.” BMC Geriatrics, № 20 (1): 506. doi: 10.1186/s12877-020-01895-z.
• Siebel, C, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, and Boos, J. 2020. “Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.” Scientific Reports, № 10 (1): 18562. doi: 10.1038/s41598-020-75662-w.
• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, and Lanvers-Kaminsky, C. 2020. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica, № Online ahead of print doi: 10.3324/haematol.2020.258525.

2019

• Lücht, UR, Weber, J, Scholz, WU, Brune, S, and Hempel, G. 2019. “Physiologically based pharmacokinetic modelling approach to assess drug-drug interactions (DDi) between psychopharmaceuticals - focus on mirtazapine and venlafaxine.” contribution to the XXVIIIth Meeting of the Population Approach Group Europe - PAGE, Stockholm, Sweden
• Hempel, G. 2019. “Pharmacotherapy in Children and Adolescents: Oncology.” in Handb Exp Pharmacol, edited by Springer. doi: 10.1007/164_2019_306.
• Lehrnbecher, T, Bochennek, K, Klingebiel, T, Gastine, S, Hempel, G, and Groll, AH. 2019. “Extended Dosing Regimens for Fungal Prophylaxis.” Clinical Microbiology Reviews, № 2019 (32(3))
• Gastine, S, Lanckohr, C, Blessou, M, Horn, D, Fobker, M, Bause, D, Hempel, G, and Ellger, B. 2019. “Pharmacokinetics of Micafungin in Critically Ill Patients.” Scientific Reports, № 9(1) doi: 10.1038/s41598-019-53093-6.
• Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, and Veal, GJ. 2019. “Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.” European Journal of Cancer, № 120 doi: 10.1016/j.ejca.2019.07.026.
• Freundt, JK, Frommeyer, G, Spieker, T, Wötzel, F, Grotthoff, JS, Stypmann, J, Hempel, G, Schäfers, M, Jacobs, AH, Eckardt, L, and Lange, PS. 2019. “Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.” BMC pharmacology & toxicology, № 2019 (20(1)) doi: 10.1186/s40360-019-0294-x.
• Pinder, N, Zimmermann, JB, Gastine, S, Würthwein, G, Hempel, G, Bruckner, T, Hoppe-Tichy, T, Weigand, MA, and Swoboda, S. 2019. “Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling.” Biomedicine & Pharmacotherapy, № 118 109318. doi: 10.1016/j.biopha.2019.109318.
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2019. “Dose adjustment of risperidone in Cytochrome P450 2D6 intermediate- and poor metabolizer based on physiologically-based pharmacokinetic model.” contribution to the Annual Meeting of the German Pharmaceutical Society – DPhG, Heidelberg, Germany
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2019. “Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach.” contribution to the Annual Meeting of the population approach group in Europe [PAGE], Stockholm, Sweden

2018

• Ellermann, I, Bueckmann, A, Eveslage, M, Buddendick, H, Latal, T, Niehoff, D, Geissler, RG, Hempel, G, Kerkhoff, A, Berdel, WE, Roeder, N, Van Aken, HK, Zarbock, A, and Steinbicker, AU. 2018. “Treating Anemia in the Preanaesthesia Assessment Clinic: Results of a Retrospective Evaluation.” Anesthesia and Analgesia, № 1 doi: 10.1213/ANE.0000000000003583.
• Völler, S, Pichlmeier, U, Zens, A, and Hempel, G. 2018. “Pharmacokinetics of recombinant asparaginase in children with achute lymphoblastic leukemia.” Cancer Chemotherapy and Pharmacology, № 81 (2): 305–314. doi: 10.1007/s00280-017-3492-5.
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, and Hensel, A. 2018. “An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.” Journal of Ethnopharmacology, № 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Perego, P, Hempel, G, Linder, S, Bradshaw, TD, Larsen, AK, Petres, GJ, and Philipps, RM. 2018. “Cellular pharmacology studies of anticancer agents:recommendations from the EORTIC-PAMM group.” Cancer Chemotherapy and Pharmacology, № 81 (3): 427–441. doi: 10.1007/s00280-017-3502-7.
• Völler, S, Pichlmeier, U, Zens, A, and Hempel, G. 2018. “Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.” Cancer Chemotherapy and Pharmacology, № 81 (2): 305–314. doi: 10.1007/s00280-17-3492-5.
• Dallmann, A, Ince, I, Coboeken, K, Eissing, T, and Hempel, G. 2018. “A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.” Clinical Pharmacokinetics, № 57 (6): 749–768. doi: 10.1007/s40262-017-0594-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, and Hempel, G. 2018. “Pharmacokinetic modeling of variconazole to develop an alternative dosing regimen in children.” Antimicrobial Agents and Chemotherapy, № 62
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, and Hensel, A. 2018. “An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.” Journal of Ethnopharmacology, № 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Lücht, UR, Weber, J, Rimmler, C, Scholz, WU, Brune, S, and Hempel, G. 2018. “Quantification of Pharmacokinetic Interactions: SCHOLZ Datenbank's MDDI-Calculator vs. Physiologically-Based Pharmacokinetic Modeling.” contribution to the Annual Meeting of the German Pharmaceutical Society - DPhG, Hamburg, Germany
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2018. “Physiologically-based Pharmacokinetic Modelling of Risperidone and its Active Metabolite 9-Hydroxyrisperidone in Subjects Genotypes for Cytochrome P450 2D6.” contribution to the Annual Meeting of the German Pharmaceutical Society – DPhG, Hamburg, Germany

2017

• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, and Hempel, G. 2017. “Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.” Clinical Pharmacokinetics, № 56 doi: 10.1007/s40262-016-0475-3.
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, M, and Boos, J. 2017. “Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.” European Journal of Drug Metabolism and Pharmacokinetics, № 42 (6): 955–963. doi: 10.1007/s13318-017-0410-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, and Hempel, G. 2017. “Pharmakokinetic Modeling of Voriconazole to Develop an Alternative Dosing Regimen in Children.” Antimicrobial Agents and Chemotherapy, № 62 (1) doi: 10.1128/AAC.01194-17.
• Dickschen, KJ, Willmann, S, Hempel, G, and Block, M. 2017. “Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.” Frontiers in Pharmacology, № 8 doi: 10.33380/fphar.2017.00067.
• Weber, J, Oberfeld, S, Bonse, A, Telger, K, Lingg, R, and Hempel, G. 2017. “Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC–MS.” Journal of Pharmaceutical and Biomedical Analysis, № 2017 (140)
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, MO, and Boos, J. 2017. “Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL.” contribution to the PAGE 26, Budapest, Ungarn
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, and Raschke, MJ. 2017. “Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg, № 88
• Mahlknecht, A, Nestler, N, Bauer, U, Schüßler, N, Schuler, J, Scharer, S, Becker, R, Waltering, I, Hempel, G, Schwalbe, O, Flamm, M, and Osterbrink, J. 2017. “Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol.” BMC Geriatrics, № 17 (1)
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, and Raschke, MJ. 2017. “Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg, № 88 (2): 95–104.
• Völler, S, Hempel, G, Würthwein, G, Boddy, AV, Krischke, M, André, N, D'Incalci, M, Bisogno, G, and Boos, J. 2017. “Towards a Model-Based Dose Recommendation for Doxorubicin in Children.” Clinical Pharmacokinetics, № 56 (3): 215–223. doi: 10.1007/s40262-016-0451-y.
• A, Dallmann, I, Ince, Solodenko, M, Meyer, S, Willmann, T, Eissing, and G, Hempel. 2017. “Physiological based pharmacokinetic modeling of renally cleared drugs in pregnant women.” Clinical Pharmacokinetics, № 2017 doi: 10.1007/s40262-017-0538-0.
• Dallmann, A, Ince, I, Meyer, M, Willmann, S, Eissing, T, and Hempel, G. 2017. “Gestation-specific changes in the anatomy and physiology of healthy pregnant women:an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy.” Clinical Pharmacokinetics, № 2017 doi: 10.1007/s40262-017-0539-z.
• Wähnert, Dirk, and Roos, AGlasbrenner J. Ilting-Reuke K. Ohrmann P. Hempel G. Duning T. Roeder N. Raschke M. 2017. “Alterstraumatologie: Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg, № 88 (2): 95–104. doi: 10.1007/s00104-016-0339-2.

2016

• Waltering, I, Schwalbe, O, and Hempel, G. 2016. “Information content of medication schedules prior to the implementation of the federal standard medication plan.” Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, № 115-1
• Krischke, M, Hempel, G, Völler, S, Andrè, N, D'Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, and Boos, J. 2016. “Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" Trial.” Cancer Chemotherapy and Pharmacology, № 21
• Bartelink, IH, Lalmohamed, A, van Reij, EM, Dvorak, CC, Savic, RM, Zwaveling, J, Bredius, RG, Egberts, AC, Bierings, M, Kletzel, M, Shaw, PJ, Nath, CE, Hempel, G, Ansari, M, Krajinovic, M, Thèoret, Y, Duval, M, Keizer, RJ, Bittencourt, H, Hassan, M, Güngör, T, Wynn, RF, Veys, P, Cuvelier, GD, Marktel, S, Chiesa, R, Cowan, MJ, Slatter, MA, Stricherz, MK, Jennissen, C, Long-Boyle, JR, and Boelens, JJ. 2016. “Association of busulfan eyposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.” The Lancet Haematology, № 13
• Usman, M, and Hempel, G. 2016. “Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).” SpringerPlus, № 5 doi: 10.1186/s40064-016-1778-4.
• John, C, Herz, T, Boos, J, Langer, K, and HempelG. 2016. “Asymmetrial flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta, № 146: 335–339.
• Lanckohr, C, Horn, D, Voeller, S, Hempel, G, Fobker, M, Welp, H, Koeck, R, and Ellger, B. 2016. “Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery.” Journal of Thoracic and Cardiovascular Surgery, № 152 (2): 603–610. doi: 10.1016/j.jtcvs.2016.04.024.
• Krischke, M, Hempel, G, Völler, S, André, N, D’Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, and Boos, J. 2016. “Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial.” Cancer Chemotherapy and Pharmacology, № 78 (6): 1175–1184. doi: 10.1007/s00280-016-3174-8.
• John, C, Herz, T, Boos, J, Langer, K, and Hempel, G. 2016. “Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta, № 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.
• Liebich, M, and Hempel, G. 2016. “Glucose as a cryoprotectant to stabilize liposomal daunorubicin (DaunoXome®) in frozen plasma for pharmacokinetic investigations.” contribution to the EORTC-PAMM Winter, Antwerpen, Begium
• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, and Hempel, G. 2016. “Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis.” contribution to the PAGE, Lissabon,Portugal

2015

• Horn, D, and Hempel, G. 2015. “Spesis.” in Angewandte Pharmakotherapie, edited by O Rose and K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G, and Ritter, J. 2015. “Leukämie.” in Angewandte Pharmakotherapie, edited by O Rose and K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Waltering, I, Schwalbe, O, and Hempel, G. 2015. “Discrepancies on Medication Plans detected in German Community Pharmacies.” Journal of Evaluation in Clinical Practice, № 21 (21(5)): 886–892.
• Völler, S, Boos, J.Krischke M, Würthwein, G, Kontny, NE, Boddy, AV, and Hempel, G. 2015. “Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.” Clinical Pharmacokinetics, № 54: 1139–1149. doi: 10.1007/s40262-015-0272-4.
• Stader, F, Wuerthwein, G, Groll, AH, Vehreschild, JJ, Cornely, OA, and Hempel, G. 2015. “Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.” Pharmaceutical Research, № 32: 2029–2037.
• Drogouti, E., Pana, Z., Tragiannidis, A., Hempel, G., and Groll, A. 2015. “Clinical pharmacology of itraconazole in children and adolescents.” Current Fungal Infection Reports, № 9 (2): 65–73. doi: 10.1007/s12281-015-0218-1.
• John, C., Herz, T., Boos, J., Langer, K., and Hempel, G. 2015. “A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.” Talanta, № 146: 335–339.
• Henrichsmann, M, and Hempel, G. 2015. “Impact of medication therapy management in patients with Parkinson's disease.” International Journal of Clinical Pharmacy, № 38 (1): 54–60. doi: 10.1007/s11096-015-0206-0.
• Goedecke, S, Mühlisch, J, Hempel, G, Frühwald, MC, and Wünsch, B. 2015. “Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O6-DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.” Electrophoresis, № 2015 doi: 10.1002/elps.201500242.

2014

• Hempel, G. 2014. “Physiology-Based Pharmacokinetic Modeling - Promise for Paediatric Drug Development?” Current Fungal Infection Reports, № 8: 67–71.
• Geier, AS, Wellmann, I, Wellmann, J, Kajüter, H, Heidinger, O, Hempel, G, and Hense, HW. 2014. “Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.” Diabetes Research and Clinical Practice, № 106: 73–80.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, and Hempel, G. 2014. “Predictive Performance of a Physilogocally Based Pharmacokinetic Model of Busulfan in Children.” Pediatric Hematology-Oncology, № 2014 (31(8)): 731–742. doi: 10.3109/08880018.2014.927945.
• Dickschen, K, Eissing, T, Mürdter, T, Schwab, M, Willmann, S, and Hempel, G. 2014. “Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.” SpringerPlus, № 5 (3): 285.
• Borghorst, S, Hempel, G, Poppenborg, S, Franke, D, König, T, and Baumgart, J. 2014. “Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.” Cancer Chemotherapy and Pharmacology, № 74: 367–378.
• Diestelhorst, C, Boos, J, McCune, JS, and Hempel, G. 2014. “Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing.” European Journal of Clinical Pharmacology, № 70 (7): 839–847. doi: 10.1007/s00228-014-1692-z.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, and Hempel, G. 2014. “Evaluation of effects of busulfan and DMA on SOS in pedriatic stem cell recipients.” Pediatric Blood and Cancer, № 61: 306–311. doi: 10.1002/pbc.24827.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, and Hempel, G. 2014. “Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.” Pediatric blood & cancer, № 61 (2): 306–311. doi: 10.1002/pbc.24827.
• Bernemann, C, Hülswig, C, Ruckert, C, Schäfer, S, Blümel, L, Hempel, G, Götte, M, Greve, B, Barth, PJ, Kiesel, L, and Liedtke, C. 2014. “Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.” Molecular Cancer, № 2014 (13): 174. doi: 10.1186/1476-4598-13-174.

2013

• Kontny, NE, Würthwein, G, Boos, J, Boddy, AV, Krischke, M, Fuhr, U, Thompson, PA, Jörger, M, Schellens, JH, and Hempel, G. 2013. “Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.” Cancer Chemotherapy and Pharmacology, № 71 (3): 749–763. doi: 10.1007/s00280-013-2069-1.
• Henschel, AD, Rothenberger, LG, Schrey, D, Gerß, J, Hempel, G, and Boos, J. 2013. “Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications.” Open Journal of Pediatrics, № 03 (02): 151–164. doi: 10.4236/ojped.2013.32027.
• Würthwein, G, Cornely, OA, Trame, M, Vehreschild, JJ, Vehreschild, MJ, Farowski, F, Müller, C, Boos, J, Hempel, G, Hallek, M, and Groll, AH. 2013. “Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.” Antimicrobial Agents and Chemotherapy, № 57 (4): 1664–1671.
• Trame, MN, Bartelink, IH, Boos, J, Boelens, JJ, and Hempel, G. 2013. “Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.” Cancer Chemotherapy and Pharmacology, № 72 (5): 1149–1155. doi: 10.1007/s00280-013-2284-9.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, and Hempel, G. 2013. “Physiologically based pharmacokinetic modelling of Busulfan: A new approach to describe and predict the pharmacokinetics in adults.” Cancer Chemotherapy and Pharmacology, № 72 (5): 991–1000. doi: 10.1007/s00280-013-2275-x.
• Geier, A.S., Wellmann, J., Wellmann, I., Kajuter, H., Heidinger, O., Hempel, G., and Hense, H.W. 2013. “Cancer detection rates following enrolment in a disease management programme for type 2 diabetes.” Diabetologia, № 56 (9): 1944–1948. doi: 10.1007/s00125-013-2947-4.

2012

• Kontny, NE, Boos, J, Würthwein, G, Hempel, G, Boddy, AV, Groll, AH, and Krischke, M. 2012. “Minization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.” Therapeutic Drug Monitoring, № 34 (4): 460–466. doi: 10.1097/FTD.0b013e31825a4d9c.
• Borghorst, S, Pieters, R, Kuehnel, HJ, Boos, J, and Hempel, G. 2012. “Population pharmacokinetics of native Escheria coli asparaginase.” Clinical Trials, № 29 (2): 154–165. doi: 10.3109/08880018.2011.627978.
• Siebert, S, Elkeles, B, Hempel, G, Kruse, J, and Smollich, M. 2012. “Die PRISCUS-Liste im klinischen Test; Praktikabilität und Vergleich mit internationalen PIM-Listen.” Zeitschrift für Gerontologie und Geriatrie, № 46: 35–47.
• Reimer, J, Bien, S, Ameling, S, Hammer, E, Völker, U, Hempel, G, Boss, J, Kroemer, HK, and Ritter, CA. 2012. “Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.” European Journal of Clinical Pharmacology, № 68 (6): 923–935. doi: 10.1007/s00228-011-1209-y.
• Kersting, G, Willmann, S, Würthwein, G, Lippert, J, Boos, J, and Hempel, G. 2012. “Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.” Cancer Chemotherapy and Pharmacology, № 69 (2): 397–405. doi: 10.1007/s00280-011-1706-9.
• Würthwein, G, Young, C, Lanvers-Kaminsky, C, Hempel, G, Trame, M, Schwerdtfeger, R, Ostermann, H, Heinz, W, Cornely, O, Kolve, H, Boos, J, Silling, G, and Groll, A. 2012. “Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.” Antimicrobial Agents and Chemotherapy, № 56 (1): 536–543. doi: 10.1128/AAC.00265-11.
• Storzinger, D., Borghorst, S., Hofer, S., Busch, C.J., Lichtenstern, C., Hempel, G., Weigand, M.A., and Hoppe-Tichy, T. 2012. “Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.” Antimicrobial Agents and Chemotherapy, № 56 (8): 4468–4470. doi: 10.1128/AAC.06167-11.
• Dickschen, K., Willmann, S., Thelen, K., Lippert, J., Hempel, G., and Eissing, T. 2012. “Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance.” Frontiers in Pharmacology, № null (null) doi: 10.3389/fphar.2012.00092.
• Falck, E., Groenhagen, A., Muhlisch, J., Hempel, G., and Wunsch, B. 2012. “Genome-wide DNA methylation level analysis by micellar electrokinetic chromatography and laser-induced fluorescence detection after treatment of cell lines with azacytidine and antifolates.” Analytical Biochemistry, № 421 (2): 439–445. doi: 10.1016/j.ab.2011.09.027.
• Fischer, U., Schuler, K., Siebert, S., Smollich, M., Elkeles, B., Hempel, G., and Kruse, J. 2012. “Formulation - Quality in seven steps. Step 1: Comply with hygiene standards.” Deutsche Apotheker-Zeitung, № 152 (37): 62–73.
• Bartelink, I.H., Boelens, J.J., Bredius, R.G.M., Egberts, A.C.G., Wang, C., Bierings, M.B., Shaw, P.J., Nath, C.E., Hempel, G., Zwaveling, J., Danhof, M., and Knibbe, C.A.J. 2012. “Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing.” Clinical Pharmacokinetics, № 51 (5): 331–345. doi: 10.2165/11598180-000000000-00000.
• Trame, MN, Bergstrand, M, Karlsson, MO, and Hempel, G. 2012. “Population Pharmacokinetics of Busulfan in Children-Response.” Clinical Cancer Research, № 18 (9): 2717–2718. doi: 10.1158/1078-0432.CCR-12-0425.

2011

• Hempel, G, and Baum, S, eds. 2011. Geriatrische Pharmazie. Eschborn: Govi.
• Horn, DG, Trame, MN, and Hempel, G. 2011. “The management of hypertensive emergencies in children after stem cell transplantation.” International Journal of Clinical Pharmacy, № 33: 165–176.
• Kontny, NE, Hempel, G, Boos, J, Boddy, AV, and Krischke, M. 2011. “Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring-using doxorubicin as an example.” Therapeutic Drug Monitoring, № 33 (6): 766–771. doi: 10.1097/FTD.0b013e31823aa8ab.
• Hempel, G., and Trame, M.N. 2011. “Therapeutic drug monitoring of busulfan.” Clinical Chemistry, № 57 (4): 643–644. doi: 10.1373/clinchem.2010.155374.
• Trame, MN, Bergstrand, M, Karlsson, MO, Boos, J, and Hempel, G. 2011. “Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.” Clinical Cancer Research, № 17 (21): 6867–6877. doi: 10.1158/1078-0432.CCR-11-0074.

2010

• Swoboda, S, Ober, MC, Lichtenstern, C, Saleh, S, Schwenger, V, Sonntag, H-G, Haefeli, WE, Hempel, G, Hoppe-Tichy, T, and Weigand, MA. 2010. “Pharmacokinetics of linezolid in septic patients with and without extended dialysis.” European Journal of Clinical Pharmacology, № 66 (3): 291–298. doi: 10.1007/s00228-009-0766-9.
• Trame, MN, Mitchell, L, Krümpel, A, Male, C, Hempel, G, and Nowak-Göttl, U. 2010. “Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: A cohort study.” Journal of Thrombosis and Haemostasis, № 8 (9): 1950–1958. doi: 10.1111/j.1538-7836.2010.03964.x.
• Hempel, G, Müller, HJ, Lanvers-Kaminsky, C, Würthwein, G, Hoppe, A, and Boos, J. 2010. “A population pharmacokinetic model for pegylated-asparaginase in children.” British Journal of Haematology, № 148 (1): 119–125. doi: 10.1111/j.1365-2141.2009.07923.x.
• Hempel, G, Relling, MV, de Rossi, G, Stary, J, De Lorenzo, P, Valsecchi, MG, Barisone, E, Boos, J, and Pieters, R. 2010. “Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.” Pediatric Blood and Cancer, № 54 (3): 355–360. doi: 10.1002/pbc.22266.
• Schrey, D, Borghorst, S, Lanvers-Kaminsky, C, Hempel, G, Gerss, J, Möricke, A, Schrappe, M, and Boos, J. 2010. “Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.” Pediatric Blood and Cancer, № 54 (7): 952–958. doi: 10.1002/pbc.22417.
• Niemann, A, Mühlisch, J, Frühwald, MC, Gerss, J, Hempel, G, and Boos, J. 2010. “Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?” Therapeutic Drug Monitoring, № 32 (4): 467–475. doi: 10.1097/FTD.0b013e3181e5c6b3.

2009

• Schrauder, A, Saleh, S, Sykora, KW, Hoy, H, Welte, K, Boos, J, Hempel, G, and Grigull, L. 2009. “Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.” Pediatric Transplantation, № 13 (4): 444–450. doi: 10.1111/j.1399-3046.2008.00968.x.
• Goedecke, S, Schlosser, S, Mühlisch, J, Hempel, G, Frühwald, MC, and Wünsch, B. 2009. “Accurate quantification of DNA methylation of DRD4 applying capillary gel electrophoresis with LIF detection.” Electrophoresis, № 30 (8): 1412–1417. doi: 10.1002/elps.200800567.
• Groll, AH, Young, C, Lanvers-Kaminsky, C, Silling, G, Hempel, G, Boos, J, and Wurthwein, G. 2009. “Population pharmacokinetics of liposomal amphotericin B, caspofungin and the combination of both in allogeneic hematopoietic stem cell recipients.” contribution to the 4th Trends in Medical Mycology, Athen, Deutschland doi: 10.1111/j.1439-0507.2009.01782.x.
• Goedecke, S, Schlosser, S, Muhlisch, J, Hempel, G, Fruhwald, MC, and Wünsch, B. 2009. “Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis.” Electrophoresis, № 30 (17): 3063–3070. doi: 10.1002/elps.200900204.

2008

• Koling, S, and Hempel, G. 2008. “Arzneimitteltherapie im Kindesalter: Die sichere und effektive Dosis finden.” Pz Prisma, № 15 (2): 68–78.
• Groenhagen, A, Kallinger, B, Hempel, G, Lanvers-Kaminsky, C, Muhlisch, J, Boos, J, Jurgens, H, and Fruhwald, MC. 2008. “The impact of antifolate therapy on the genome and epigenome.” Klinische Pädiatrie, № 220 (3): 201–201.
• Niemann, A, Boos, J, Muhlisch, J, Fruhwald, MC, and Hempel, G. 2008. “Determination of methotrexate and its main metabolite in cerebrospinal fluid after High-Dose Methotrexate by LC-MS.” Klinische Pädiatrie, № 220 (3): 205–205.
• Hempel, G. 2008. “Kommentar zur Monographie Paclitaxel des Europäischen Arzneibuchs.” in Kommentar zum Ph. Eur. Ausgabe 5.8, edited by G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

2007

• Hempel, G, and Boos, J. 2007. “Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. [J. Chromatogr. B 850 (2007) 569-574].” Journal of Chromatography B, № 853 (1-2): 369–370.
• Hempel, G, Oechtering, D, Lanvers-Kaminsky, C, Klingebiel, T, Vormoor, J, Gruhn, B, and Boos, J. 2007. “Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.” Journal of Clinical Oncology, № 25 (13): 1772–1778. doi: 10.1200/JCO.2006.08.8807.
• Hempel, G, and Boos, J. 2007. “Flat-fixed dosing versus body surface area-based dosing of anticancer drugs: There is a difference.” Oncologist, № 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Koling, S, Hempel, G, Lanvers, C, Boos, J, and Würthwein, G. 2007. “Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases.” International Journal of Clinical Pharmacology and Therapeutics, № 45 (9): 496–503. doi: 10.5414/cpp45496.
• Hunz, M, Jetter, A, Warm, M, Pantke, E, Tuscher, M, Hempel, G, Jaehde, U, Untch, M, Kurbacher, C, and Fuhr, U. 2007. “Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.” Clinical Pharmacology and Therapeutics, № 81 (5): 659–668. doi: 10.1038/sj.clpt.6100067.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Féty, R, De Bruijn, E, Hempel, G, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Twelves, C, Beijnen, JH, and Schellens, JHM. 2007. “Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG.” Clinical Pharmacokinetics, № 46 (12): 1051–1068. doi: 10.2165/00003088-200746120-00005.
• Wilde, S, Jetter, A, Rietbrock, S, Kasel, D, Engert, A, Josting, A, Klimm, B, Hempel, G, Reif, S, Jaehde, U, Merkel, U, Busse, D, Schwab, M, Diehl, V, and Fuhr, U. 2007. “Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.” Clinical Pharmacokinetics, № 46 (4): 319–333. doi: 10.2165/00003088-200746040-00005.
• Hempel, G, and Boos, J. 2007. “Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. J. Chromatogr. B 850 (2007) 569-574.” Journal of Chromatography B, № 853 (1-2): 369–370. doi: 10.1016/j.jchromb.2007.02.060.
• Hempel, G, and Boos, J. 2007. “Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.” Oncologist, № 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Hempel, G. 2007. “Populationspharmakokinetik.” in Repetitorium Klinische Pharmazie, edited by P Högger and E Strehl. Eschborn: Govi.
• Hempel, G. 2007. “Pharmakogenetik.” in Repetitorium Klinische Pharmazie, edited by P Högger and E Strehl. Eschborn: Govi.
• Armstrong, JK, Hempel, G, Koling, S, Chan, LS, Fisher, T, Meiselman, HJ, and Garratty, G. 2007. “Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.” Cancer, № 110 (1): 103–111. doi: 10.1002/cncr.22739.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Calvert, AH, Boddy, A, Hollema, H, Fety, R, Van der, Vijgh W JF, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Beijnen, JH, and Schellens, JHM. 2007. “Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG.” British Journal of Clinical Pharmacology, № 63 (4): 505–505. doi: 10.1111/j.1365-2125.2007.02886_4.x.

2006

• Ünsalan, S, Hempel, G, Fobker, M, Würthwein, G, and Boos, J. 2006. “Monitoring of mycophenolic acid in the plasma of transplant patients by capillary electrophoresis.” Chromatographia, № 64 (7-8): 419–421. doi: 10.1365/s10337-006-0046-0.
• Oechtering, D, Boos, J, and Hempel, G. 2006. “Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.” Journal of Chromatography B, № 838 (2): 129–134. doi: 10.1016/j.jchromb.2006.04.034.
• Saleh, S, and Hempel, G. 2006. “Quantification of ganciclovir in human plasma using capillary electrophoresis.” Electrophoresis, № 27 (12): 2439–2443. doi: 10.1002/elps.200500903.
• Lanvers-Kaminsky, C, and Hempel, G. 2006. “Preclinical and Clinical Aspects of Asparaginase.” European Journal of Hospital Pharmacy: Science and Practice, № 12 (5): 45–46.
• Hempel, G. 2006. “Kommentar zur Monographie Buspironhydrochlorid des Europäischen Arzneibuchs.” in Kommentar zum Ph. Eur. Ausgabe 5.4, edited by G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G. 2006. “Kommentar zur Monographie Emedastindifumarat des Europäischen Arzneibuchs.” in Kommentar zum Ph. Eur. Ausgabe 5.4, edited by G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

2005

• Lingg, RM, Hempel, G, Rots, MG, Van Zantwijk, CH, Boos, J, and Kaspers, GJL. 2005. “Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.” Cancer Chemotherapy and Pharmacology, № 56 (3): 322–327. doi: 10.1007/s00280-005-1032-1.
• Hempel, G, Lingg, R, and Boos, J. 2005. “Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: Implications for the application in case of methotrexate intoxications.” Cancer Chemotherapy and Pharmacology, № 55 (4): 347–353. doi: 10.1007/s00280-004-0910-2.
• Oechtering, D, Schiltmeyer, B, Hempel, G, Schwab, M, Würthwein, G, Mürdter, T, Klingebiel, T, Vormoor, J, Gruhn, B, Fleischack, G, and Boos, J. 2005. “Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.” Anti-Cancer Drugs, № 16 (3): 337–344. doi: 10.1097/00001813-200503000-00014.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, and Boos, J. 2005. “Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.” European Journal of Clinical Pharmacology, № 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.
• Würthwein, G, Groll, AH, Hempel, G, Adler-Shohet, FC, Lieberman, JM, and Walsh, TJ. 2005. “Population pharmacokinetics of amphotericin B lipid complex in neonates.” Antimicrobial Agents and Chemotherapy, № 49 (12): 5092–5098. doi: 10.1128/AAC.49.12.5092-5098.2005.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, and Boos, J. 2005. “Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.” European Journal of Clinical Pharmacology, № 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.

2004

• Hempel, G. 2004. “Dose and therapy individualisation in cancer chemotherapy.” in Drug Monitoring and Clinical Chemistry, Handbook of Analytical Seperations Vol 5, edited by G Hempel. Amsterdam: Elsevier. doi: 10.1016/S1567-7192(04)80008-1.

2003

• Flege, S, Griese, N, and Hempel, G. 2003. “Drug Monitoring von Anthrazyklinen: Teil 1: Chemie, Wirkung, Nebenwirkung und Pharmakokinetik.” Pz Prisma, № 10 (1): 29–36.
• Flege, S, Griese, N, and Hempel, G. 2003. “Drug Monitoring von Anthrazyklinen Teil 2: Monitoring bei Kindern, Reduktion der Kardiotoxizität, Fallbeispiele.” Pz Prisma, № 10 (2): 105–117.
• Hempel, G, Reinhardt, D, Creutzig, U, and Boos, J. 2003. “Population pharmacokinetics of liposomal daunorubicin in children.” British Journal of Clinical Pharmacology, № 56 (4): 370–377. doi: 10.1046/j.1365-2125.2003.01886.x.
• Hempel, G, Rübe, C, Mosler, C, Wienstroer, M, Wagner-Bohn, A, Schuck, A, Willich, N, and Boos, J. 2003. “Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors.” Anti-Cancer Drugs, № 14 (6): 417–422. doi: 10.1097/00001813-200307000-00005.
• Schiltmeyer, B, Klingebiel, T, Schwab, M, Mürdter, TE, Ritter, CA, Jenke, A, Ehninger, G, Gruhn, B, Würthwein, G, Boos, J, and Hempel, G. 2003. “Population pharmacokinetics of oral busulfan in children.” Cancer Chemotherapy and Pharmacology, № 52 (3): 209–216. doi: 10.1007/s00280-003-0631-y.
• Hempel, G. 2003. “Biomedical applications of capillary electrophoresis.” Clinical Chemistry and Laboratory Medicine, № 41 (6): 720–723. doi: 10.1515/CCLM.2003.111.

2002

• Griese, N, Blaschke, G, Boos, J, and Hempel, G. 2002. “Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.” Journal of Chromatography A, № 979 (1-2): 379–388. doi: 10.1016/S0021-9673(02)01440-1.
• Lingg, RM, Rots, MG, Van Zantwijk, CH, Hempel, G, Kaspers, GJL, and Boos, J. 2002. “Effect and interaction of 7-hydroxy methotrexate and methotrexate in AML and ALL patients samples: Measured by the thymidylate synthase inhibition assay.” International Journal of Clinical Pharmacology and Therapeutics, № 40 (8): 382–384.
• Hempel, G, Flege, S, Würthwein, G, and Boos, J. 2002. “Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.” Cancer Chemotherapy and Pharmacology, № 49 (2): 133–141. doi: 10.1007/s00280-001-0392-4.
• Busse, D, Würthwein, G, Hinske, C, Hempel, G, Fromm, MF, Eichelbaum, M, Kroemer, HK, and Busch, FW. 2002. “Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration.” Naunyn-Schmiedeberg's Archives of Pharmacology, № 366 (3): 218–225. doi: 10.1007/s00210-002-0594-2.
• Schiltmeyer, B, Hempel, G, Schwab, M, Ritter, C, Klingebiel, T, and Boos, J. 2002. “Population pharmacokinetics of oral busulfan in children.” International Journal of Clinical Pharmacology and Therapeutics, № 40 (8): 385–386.
• Reinhardt, D, Hempel, G, Fleischhack, G, Schulz, A, Boos, J, and Creutzig, U. 2002. “Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin.” Klinische Pädiatrie, № 214 (4): 188–194. doi: 10.1055/s-2002-33185.
• Wilde, S, Jetter, A, Zaigier, M, Rietbrock, S, Menzel, H, Sieber, M, Tesch, H, Hempel, G, Busse, D, Schwab, M, Reif, S, Jaehde, U, Diehl, V, and Fuhr, U. 2002. “Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.” International Journal of Clinical Pharmacology and Therapeutics, № 40 (12): 586–588.
• Lanvers, C, Pinheiro, JPV, Hempel, G, Wuerthwein, G, and Boos, J. 2002. “Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.” Analytical Biochemistry, № 309 (1): 117–126. doi: 10.1016/S0003-2697(02)00232-4.

2001

• Ünsalan, S, Hempel, G, Boos, J, and Blaschke, G. 2001. “Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis.” Chromatographia, № 54 (9-10): 635–637. doi: 10.1007/BF02492191.
• Laubrock, N, Schulze-Westhoff, P, Würthwein, G, Flege, S, Lanvers, C, and Hempel, G. 2001. “Drug-monitoring von Anthracyclinen - Untersuchungen zur Minimierung präanalytischer Fehler bei der Gewinnung von Plasmaproben.” Krankenhauspharmazie KPH, № 22 (4): 166–169.
• Wessel, T, Breitkreutz, J, Ahlke, E, Hempel, G, and Boos, J. 2001. “Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.” Krankenhauspharmazie KPH, № 22 (7): 325–329.
• Hempel, G, Schulze-Westhoff, P, Flege, S, and Boos, J. 2001. “Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.” Journal of chromatography B: Biomedical sciences and applications, № 758 (2): 221–228. doi: 10.1016/S0378-4347(01)00185-2.
• Soetebeer, UB, Schierenberg, M-O, Schulz, H, Hempel, G, Andresen, P, and Blaschke, G. 2001. “Simultaneous quantification of etoposide and etoposide phosphate in human plasma by capillary electrophoresis using laser-induced native fluorescence detection.” Analytical Chemistry, № 73 (10): 2178–2182. doi: 10.1021/ac001467v.
• Torsten, Wessel, Jörg, Breitkreutz, Elvira, Ahlke, Georg, Hempel, and Joachim, Boos. 2001. “Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.” Krankenhauspharmazie, № 22 (7): 325–329.
• Flege, S, Hempel, G, Schulze-Westhoff, P, Laubrock, N, and Boos, J. 2001. “Drug Monitoring of Doxorubicin in Children.” in Acute Leukemias VIII, Vol. 40 of Haematology and Blood Transfusion, edited by T Büchner, W Hiddemann, B Wörmann, G Schellong, J Ritter and U Creutzig. Düsseldorf: Springer VDI Verlag.
• Wessel, T, Hempel, G, and Boos, J. 2001. “Drug Monitoring during Maintenance Therapy in Children with ALL.” in Acute Leukemias VIII, Vol. 40 of Haematology and Blood Transfusion, edited by T Büchner, W Hiddemann, B Wörmann, G Schellong, J Ritter and U Creutzig. Düsseldorf: Springer VDI Verlag. doi: 10.1007/978-3-642-18156-6_40.